Aptose to Present at September Investor Conferences
September 09, 2020 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference
August 06, 2020 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020
July 21, 2020 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Announces Pricing of Public Offering of Common Shares
July 15, 2020 22:49 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced...
Aptose Announces Proposed Public Offering of Common Shares
July 15, 2020 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten public...
Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia
June 29, 2020 07:01 ET
|
Aptose Biosciences, Inc.
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML Phase 1a/b study in B-cell malignancies continues through dose escalation SAN DIEGO and TORONTO,...
Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
June 12, 2020 07:00 ET
|
Aptose Biosciences, Inc.
Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies Plasma from CG-806 treated patients completely inhibited...
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
June 02, 2020 17:49 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 02, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
May 14, 2020 09:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 14, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference
May 07, 2020 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...